Fuller & Thaler Asset Management
ANIP icon

Fuller & Thaler Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,070
Closed -$464K – 501
2025
Q3 		$464K Buy
+5,070
New +$413K ﹤0.01% 437
2022
Q3 		– Sell
-46,658
Closed -$1.38M – 468
2022
Q2 		$1.38M Buy
46,658
+200
+0.4% +$5.77K 0.01% 374
2022
Q1 		$1.31M Buy
+46,458
New +$1.73M 0.01% 395

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management's ANIP Position: Q4 2025 in Review

Fuller & Thaler Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 5,070 shares — an estimated $464K sold.

Fuller & Thaler Asset Management first reported a position in ANIP in Q1 2022 and held it in 3 quarters. The position peaked at $1.38M in Q2 2022. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Fuller & Thaler Asset Management reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 5,070 ANI Pharmaceuticals shares in Q4 2025, an estimated $464K.
  • Fuller & Thaler Asset Management first reported a position in ANI Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's ANI Pharmaceuticals position peaked at $1.38M in Q2 2022.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2025, filed 12 Feb 2026.